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Background
The purpose of this study was: aim 1) compare insulin
and leucine serum responses after feeding a novel
hydrolyzed whey protein (WPH)-based supplement ver-
sus a whey protein isolate (WPI) in rats during the
post-absorptive state, and aim 2) to perform toxicologi-
cal analysis on rats that were fed different doses of the
novel WPH-based supplement over a 30-day period.
Methods
In male Wistar rats (~250 g, n = 40), serum insulin and
leucine concentrations were quantified up to 120 min
after one human equivalent dose of a WPI or the WPH-
based supplement. In a second group of rats (~250 g, n
= 20), we examined serum/blood and liver/kidney histo-
pathological markers after 30 days of feeding low
(1human equivalent dose), medium (3 doses) and high
(6 doses) amounts of the WPH-based supplement.
Results
In aim 1, leucine levels were significantly higher at 15
min after WPH vs. WPI ingestion (p = 0.04) followed by
higher insulin concentrations at 60 min (p = 0.002). In
aim 2, liver and kidney histopathology/toxicology mar-
kers were not different 30 days after feeding with low,
medium, high dose WPH-based supplementation or
water only. There were no between-group differences in
body fat or lean mass or circulating clinical chemistry
markers following the 30-day feeding intervention in
aim 2.
Conclusion
In comparison to WPI, acute ingestion of a novel WPH-
based supplement resulted in a higher transient leucine
response with a sequential increase in insulin. Further-
more, chronic ingestion of the tested whey protein
hydrolysate supplement appears safe.
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